Promising drug combo targets tough breast cancer after surgery
NCT ID NCT03945721
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 24 times
Summary
This early-phase study tests the drug niraparib given together with radiation therapy after surgery for triple negative breast cancer. It includes 21 patients who still had cancer cells after chemotherapy. The main goal is to find the safest dose of niraparib and see if the combination helps prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.